Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05874310
Study type	Interventional
Source	Frontera Therapeutics
Contact	Xinyan Li
Phone	+86-021-58206061
Email	xinyan.li@fronteratherapeutics.com
Status	Recruiting
Phase	Early Phase 1
Start date	February 1, 2023
Completion date	November 1, 2027

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04926129` - Natural History of the Progression of X-Linked Retinitis Pigmentosa
	Recruiting	`NCT05926583` - A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa	Phase 3
	Enrolling by invitation	`NCT06275620` - A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)	Phase 2
	Completed	`NCT03116113` - A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112	Phase 1/Phase 2
	Recruiting	`NCT04850118` - A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP	Phase 2/Phase 3
	Active, not recruiting	`NCT04517149` - 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)	Phase 1/Phase 2
	Enrolling by invitation	`NCT03584165` - Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa	Phase 3
	Active, not recruiting	`NCT04312672` - Long-term Follow-up Gene Therapy Study for RPGR- XLRP
	Completed	`NCT04868916` - An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
	Completed	`NCT03252847` - Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)	Phase 1/Phase 2
	Active, not recruiting	`NCT04671433` - Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Phase 3
	Active, not recruiting	`NCT04794101` - Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Phase 3
	Completed	`NCT03314207` - Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
	Active, not recruiting	`NCT03316560` - Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations	Phase 1/Phase 2
	Active, not recruiting	`NCT06333249` - A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)	Phase 2